ELZANOR 12.5/1000MG TABLET

ELZANOR 12.5/1000MG TABLET is a combination medication containing two active ingredients: EMPAGLIFLOZIN+METFORMIN. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin is a biguanide. Together, they work to control blood sugar levels in individuals with type 2 diabetes.

Uses:

1. Type 2 Diabetes Mellitus:
   • ELZANOR is prescribed for the management of type 2 diabetes mellitus in adults. It is typically recommended when blood sugar levels are not adequately controlled through diet and exercise alone.

Components and Mechanism of Action:

1. Empagliflozin:
   • Empagliflozin inhibits the reabsorption of glucose in the kidneys, leading to increased urinary excretion of glucose and, consequently, a reduction in blood sugar levels.
2. Metformin:
   • Metformin improves the body’s response to insulin, reduces the production of glucose by the liver, and enhances the uptake of glucose by tissues, contributing to better blood sugar control.

Side Effects:

Common side effects may include:

• Genital yeast infections (for empagliflozin)
• Gastrointestinal disturbances (e.g., nausea, diarrhea) for metformin
• Increased urination

Serious side effects may include:

• Lactic acidosis (for metformin)
• Hypotension (low blood pressure)
• Ketoacidosis (for empagliflozin)

When Not to Use:

1. Type 1 Diabetes:
   • ELZANOR is not intended for the treatment of type 1 diabetes.
2. Hypersensitivity:
   • Individuals with a known hypersensitivity to empagliflozin, metformin, or any components of the formulation should avoid using this medication.

Precautions and Warnings:

• Renal Impairment:
  • ELZANOR should be used with caution in individuals with renal impairment, as both empagliflozin and metformin are excreted by the kidneys.
• Lactic Acidosis:
  • Metformin may increase the risk of lactic acidosis, particularly in patients with conditions such as renal impairment or congestive heart failure.
• Dehydration:
  • Empagliflozin may lead to dehydration, especially in elderly patients or those with low blood volume.

Dosage and Administration:

• The dosage of ELZANOR should be individualized based on the patient’s condition and response to treatment. It is typically taken orally, with or without food.

Patients should follow their healthcare provider’s instructions, monitor for any unusual symptoms, and report side effects promptly. This information is not exhaustive, and healthcare providers should refer to the prescribing information for a comprehensive understanding of the medication.